adapalene vs erythromycin topical
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and erythromycin topical. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Erygel
No summary available.
Erythromycin topical solution is a medicine that you put on your skin to treat acne. It contains an antibiotic to help clear up acne.
Information not available.
This medicine treats acne vulgaris, a common skin condition. It helps reduce acne on your face, neck, shoulders, chest, and back. Use it as directed by your doctor to improve your skin.
Information not available.
Erythromycin is a macrolide antibiotic. It works by stopping the growth of bacteria that cause acne. This helps to reduce inflammation and clear up your skin.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Peeling skin
- • Dry skin
- • Itching
- • Redness
- • Oily skin
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
No adverse event reports.
No specific warnings noted.
You should not use this medicine if you are allergic to any of its ingredients.
No pregnancy information available.
It is not known if this medicine will harm an unborn baby. Talk to your doctor if you are pregnant or breastfeeding before using this medicine.
Also Compare, Nearby Drugs
Compare adapalene with
Compare erythromycin topical with
How to Read This adapalene vs erythromycin topical Comparison
adapalene is classified in the Retinoid (Topical) drug class, while erythromycin topical sits within the Topical Antibiotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while erythromycin topical has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or erythromycin topical.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.